Fennec Pharmaceuticals Inc. (TSX: FRX)

Market Cap	236.13M
Revenue (ttm)	66.67M
Net Income (ttm)	-1.53M
Shares Out	n/a
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,800
Open	8.48
Previous Close	8.46
Day's Range	8.47 - 8.57
52-Week Range	5.65 - 15.43
Beta	0.25
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 27, 2025

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is ba...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 29
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: FRX

Financial Performance

In 2023, Fennec Pharmaceuticals's revenue was $21.25 million, an increase of 1284.50% compared to the previous year's $1.54 million. Losses were -$16.05 million, -32.34% less than in 2022.

Financial numbers in USD